Characteristics Value patients (%)
Sex   Male/Female 16/6
Age: median (range) at first Allo-HCT
Age: median (range) at second Allo-HSCT
35 years (18-49)
37 years (20-49)
Diagnosis N (%)
Acute Myeloblastic Leukemia
Chronic myeloid leukemia
Acute lymphoblastic leukemia
Medullary Aplasia
Non Hodgkin lymphoma
paroxysmal nocturnal hemoglobinuria
 9 (41%)
5 (22%)
4 (18%)
2 (9%)
1 (5%)
1 (5%)
Donor origin at the second Allo-HCT
Same donor
Other donor
  14 (64%)
8   (36%)
Cause of the second Allo-HCT
Progression
Graft Failure
Graft failure and progression
  14(64%)
6 (27%)
2 (9%)
AML: Acute Myeloid Leukaemia; CR: Complete Remission; ALL: Acute Lymphoid
Leukaemia; CML: Chronic Myeloid Leukaemia; TBI: Total Body Irradiation; GVHD:
Graft-Versus-Host Disease; PBSC: Peripheral Blood Progenitor Cells; OS: Overall
survival; DFS: Disease-Free Survival; M: Male; F: Female; T: Transplant; TRM:
Transplant-Related Mortality
Table1: Patients Characteristics